[HTML][HTML] Modern risk stratification of acute myeloid leukemia in 2023: integrating established and emerging prognostic factors
E Boscaro, I Urbino, FM Catania, G Arrigo, C Secreto… - Cancers, 2023 - mdpi.com
Simple Summary Several factors, both patient-and disease-related, are essential to
accurately estimate acute myeloid leukemia (AML) prognosis. The rapidly evolving field …
accurately estimate acute myeloid leukemia (AML) prognosis. The rapidly evolving field …
[HTML][HTML] Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse Genetics
N Santoro, P Salutari, M Di Ianni, A Marra - International Journal of …, 2024 - mdpi.com
The treatment of acute myeloid leukemia (AML) with adverse genetics remains
unsatisfactory, with very low response rates to standard chemotherapy and shorter durations …
unsatisfactory, with very low response rates to standard chemotherapy and shorter durations …
Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms
During the past decade, the outcomes of pediatric patients with acute myeloid leukemia
(AML) have plateaued with 5‐year event‐free survival (EFS) and overall survival (OS) of …
(AML) have plateaued with 5‐year event‐free survival (EFS) and overall survival (OS) of …
A Pre-Leukemic DNA Methylation Signature in Healthy Individuals at Higher Risk for Developing Myeloid Malignancy
Purpose: DNA methylation alterations are widespread in acute myelogenous leukemia
(AML) and myelodysplastic syndrome (MDS), some of which appear to have evolved …
(AML) and myelodysplastic syndrome (MDS), some of which appear to have evolved …
Genetic or pharmacological inactivation of CREBBP sensitizes B-cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition
A Garcia-Gimenez, JE Ditcham, DMA Azazi, E Meduri… - bioRxiv, 2023 - biorxiv.org
B-cell acute lymphoblastic leukemia (B-ALL) is a leading cause of death in childhood and
outcomes in adults remain dismal. There is therefore an urgent clinical need for therapies …
outcomes in adults remain dismal. There is therefore an urgent clinical need for therapies …
Machine learning investigation of gene expression datasets reveals TP53 mutant-like AML with wild type TP53 and poor prognosis
Acute myeloid leukemia (AML) with TP53 mutations (TP53Mut) has poor clinical outcomes
with 1-year survival rates of less than 10%. We investigated whether this AML subtype …
with 1-year survival rates of less than 10%. We investigated whether this AML subtype …
Machine Learning Analysis of Gene Expression Reveals TP53 Mutant-like AML With Wild Type TP53 And Poor Prognosis
Machine Learning Analysis of Gene Expression Reveals TP53 Mutant-like AML With Wild
Type TP53 And Poor Prognosis Page 1 Machine Learning Analysis of Gene Expression …
Type TP53 And Poor Prognosis Page 1 Machine Learning Analysis of Gene Expression …